Podcasts

He talks about the challenges of treating progressive psoriatic arthritis, why certain patients progress to more severe disease, and how to change medication when needed.

Adam Cheifetz, MD, a cochair of the virtual Interdisciplinary Autoimmune Summit (IAS) 2020, gives an overview of his presentation on how proactive and reactive therapeutic drug monitoring differ and how the proactive approach can significantly benefit patients with autoimmune diseases.

She discusses her research on assays for measuring drug concentrations and anti-drug antibodies, as well as algorithmic approaches to proactive therapeutic drug monitoring and how they help patients with IBD achieve and maintain remission.

In this podcast, Parambir Dulai, MD, discusses his recent research on treating inflammatory bowel disease to achieve endoscopic remission, through the use of a treat-to-target approach using algorithmic treatment adjustments.

In this podcast, gastroenterologist David Hudesman, MD, and rheumatologist José Scher, MD, discuss their prospective case series involving patients with known immune-mediated inflammatory diseases who were receiving anticytokine biologics, other immunomodulatory therapies, or both when confirmed or highly suspected symptomatic COVID-19 developed.

He talks about his study that evaluated the influence of distinct domains of rheumatoid arthritis disease activity, functional limitation, mood disturbance, as well as RA-specific knowledge and patients’ beliefs about medications on treatment adherence.

He talks about his research on highly sensitive cardiac troponin-I and IgA antibodies against β-2 glycoprotein 1 in the setting of coronary atherosclerosis among patients with rheumatoid arthritis.

In this podcast, Tanaz Kermani, MD, MS, provides an in-depth overview of antineutrophil cytoplasmic antibody-associated vasculitis treatment strategies.

Matthew Grissinger, RPh, FISMP, FASCP, discusses concerns related to drug shortages associated with the COVID-19 pandemic that dermatologists and rheumatologists should be aware of and steps they can take to prepare themselves and their patients for possible interruptions.

Lawrence Green, MD, section editor of The Dermatologist’s Psoriasis Center of Excellence and clinical professor at George Washington School of Medicine, shares his pearls on implementing the National Psoriasis Foundation’s treat-to-target approach.